Cholinesterase inhibitors are a group of drugs recommended for the treatment of Alzheimer’s disease, but their effects on cognition have been debated and few studies have investigated their long-term effects. A new study shows persisting cognitive benefits and reduced mortality for up to five years after diagnosis.